| Ytd | 58.08% | |
| 1y | -28.24% |
| Open | 11.72 | Prev Close | 11.53 | Low | 11.70 | High | 11.90 | Mkt Cap | 4.01B |
| Vol | 170.69K | Avg Vol | 187.10K | EPS | -0.02 | P/E | N/A | Forward P/E | 49.58 |
| Beta | 0.59 | Short Ratio | 1.08 | Inst. Own | 0.81% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-25 | 50-d Avg | 10.22 | 200-d Avg | 9.21 | 1yr Est | 20.51 |
TLX News
Telix Pharmaceuticals Limited (TLX) Discusses Neurologic Oncology Portfolio and Advances in Therapeu
Partnership to evaluate Telix's innovative precision medicine products and candidates in combina
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces that the IPAX-
Regeneron melanoma combo trial missed its main goal against Keytruda despite longer progression-free
Telix to partner with companies developing advanced minimally invasive and image-guided ablative tec
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces the publicatio
MELBOURNE, Australia and INDIANAPOLIS, April 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limi
US stock futures mixed, Nasdaq 100 up over 50 points. JPMorgan shares down 3.1% after beating earnin
Telix collaborates with Regeneron, targeting radiopharmaceutical development, with milestones up to
Wedbush analyst David Nierengarten reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a Outperfor
HC Wainwright & Co. analyst Robert Burns reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a
Collaboration is a 50/50 cost and profit-sharing model and combines Telix's expertise in radioph
FDA accepts Telix NDA for Pixclara for brain cancer imaging, analysts see confidence rebuild amid st
Telix Pharma stock climbs on strong Q1 growth and Phase 3 study success. Analysts maintain Buy ratin
Wedbush analyst David Nierengarten reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a Outperfor
HC Wainwright & Co. analyst Robert Burns reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a
Telix Pharma's ProstACT study achieves primary objectives, positioning TLX591-Tx as potential fi
Key findings include:Tolerability profile supported by dosimetry and low-grade non-hematologic event
Citigroup analyst Laura Sutcliffe maintains Telix Pharmaceuticals (NASDAQ:TLX) with a Buy and rai
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces that it has su
Telix Pharmaceuticals meets its FY25 revenue target with strong Q4 growth, expanded U.S. launches an
HC Wainwright & Co. analyst Robert Burns reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces that the first
HC Wainwright & Co. analyst Robert Burns reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces a strategic cl
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces results from t
Telix Pharmaceuticals posts 53% Q3 revenue growth to $206 million, lifts FY25 guidance to up to $820
Telix Pharmaceuticals (NASDAQ:TLX) raises FY2025 sales outlook from $770.000 million-$800.000 millio
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces that the Unite
Citigroup analyst Laura Sutcliffe initiates coverage on Telix Pharmaceuticals (NASDAQ:TLX) with a
HC Wainwright & Co. analyst Robert Burns maintains Telix Pharmaceuticals (NASDAQ:TLX) with a
FDA sent a second CRL to Telix, delaying its kidney cancer PET drug. Analysts weigh pricing pressure
Wedbush analyst David Nierengarten reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a Outperfor
Shares of Vicor Corporation (NASDAQ:VICR) rose sharply in pre-market trading after posting second-qu
Telix Pharmaceuticals is advancing TLX592, which is designed for a faster elimination from circulati
Top mid-cap stock performers last week: AGL, RXRX, CERT, AVAV, STRL, ORLA, IAG, SBSW, LOAR, RYTM, TL
